Eli Lilly Stock Exceeds $1,000 Without Split Announcement

Eli Lilly and Company has seen its share price rise above $1,000 and approach $1,200, driven by its dominance in the anti-obesity drug market. This growth has pushed the company's total valuation beyond $1 trillion.

Despite the high share price, the company has not announced a stock split. While investors typically expect splits at these levels to increase share accessibility, Eli Lilly has not executed such an action since 1997. CEO David A. Ricks has provided no indication that a split is forthcoming, maintaining a discretionary approach to corporate stock actions.